Sino Biopharmaceutical Limited Receives Acceptance for New Indication Application of Culmerciclib Capsule for First-Line Breast Cancer Treatment
Reuters
Jul 10, 2025
<a href="https://laohu8.com/S/SBHMY">Sino Biopharmaceutical</a> Limited Receives Acceptance for New Indication Application of Culmerciclib Capsule for First-Line Breast <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>
Sino Biopharmaceutical Limited has announced the acceptance of a new indication application for the marketing of its Culmerciclib Capsule. This capsule is designed for the first-line treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer. The application has been submitted to the Centre for Drug Evaluation of the National Medical Products Administration of the PRC and has been accepted for review. This development marks a significant step forward in the company's efforts to provide advanced treatment options for breast cancer patients. The Culmerciclib Capsule, a CDK2/4/6 inhibitor, is to be used in combination with fulvestrant injection and has undergone a Phase III clinical study to evaluate its efficacy and safety.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.